dc.contributor.author | Milighetti, M | |
dc.contributor.author | Krasny, L | |
dc.contributor.author | Lee, ATJ | |
dc.contributor.author | Morani, G | |
dc.contributor.author | Szecsei, C | |
dc.contributor.author | Chen, Y | |
dc.contributor.author | Guljar, N | |
dc.contributor.author | McCarthy, F | |
dc.contributor.author | Wilding, CP | |
dc.contributor.author | Arthur, A | |
dc.contributor.author | Fisher, C | |
dc.contributor.author | Judson, I | |
dc.contributor.author | Thway, K | |
dc.contributor.author | Cheang, MCU | |
dc.contributor.author | Jones, RL | |
dc.contributor.author | Huang, PH | |
dc.date.accessioned | 2021-07-02T11:10:59Z | |
dc.date.available | 2021-07-02T11:10:59Z | |
dc.date.issued | 2021-06-15 | |
dc.identifier.citation | Journal of proteomics, 2021, 241 pp. 104236 - ? | |
dc.identifier.issn | 1874-3919 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4667 | |
dc.identifier.eissn | 1876-7737 | |
dc.identifier.doi | 10.1016/j.jprot.2021.104236 | |
dc.description.abstract | Soft tissue sarcomas (STS) are a group of rare and heterogeneous cancers. While large-scale genomic and epigenomic profiling of STS have been undertaken, proteomic analysis has thus far been limited. Here we utilise sequential window acquisition of all theoretical fragment ion spectra mass spectrometry (SWATH-MS) for proteomic profiling of formalin fixed paraffin embedded (FFPE) specimens from a cohort of STS patients (n = 36) across four histological subtypes (leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma). We quantified 2951 proteins across all cases and show that there is a significant enrichment of gene sets associated with smooth muscle contraction in leiomyosarcoma, RNA splicing regulation in synovial sarcoma and leukocyte activation in undifferentiated pleomorphic sarcoma. We further identified a subgroup of STS cases that have a distinct expression profile in a panel of proteins, with worse survival outcomes when compared to the rest of the cohort. Our study highlights the value of comprehensive proteomic characterisation as a means to identify histotype-specific STS profiles that describe key biological pathways of clinical and therapeutic relevance; as well as for discovering new prognostic biomarkers in this group of rare and difficult-to-treat diseases. | |
dc.format | Print-Electronic | |
dc.format.extent | 104236 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Leiomyosarcoma | |
dc.subject | Sarcoma | |
dc.subject | Gene Expression Profiling | |
dc.subject | Proteomics | |
dc.subject | Mass Spectrometry | |
dc.title | Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-04-14 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1016/j.jprot.2021.104236 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Journal of proteomics | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Genomic Analysis – Clinical Trials | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Genomic Analysis – Clinical Trials | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 241 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Genomic Analysis – Clinical Trials | |
icr.researchteam | Sarcoma Clinical Trials (R Jones) | |
icr.researchteam | Molecular and Systems Oncology | |
icr.researchteam | Genomic Analysis – Clinical Trials | |
icr.researchteam | Sarcoma Clinical Trials (R Jones) | |
icr.researchteam | Molecular and Systems Oncology | |
dc.contributor.icrauthor | Krasny, Lukas | |
dc.contributor.icrauthor | Wilding, Christopher | |
dc.contributor.icrauthor | Arthur, Amani | |
dc.contributor.icrauthor | Cheang, Chon | |
dc.contributor.icrauthor | Huang, Paul | |